Équipe 1 – Publications

À LA UNE

Pour connaitre nos dernières publications
rendez-vous sur PubMed

logo PubMed
Équipe Alzheimer et Tauopathies
Vous êtes ici : Accueil > Alzheimer et Tauopathies > PUBLICATIONS

ÉQUIPE ALZHEIMER & TAUOPATHIES

PUBLICATIONS

PUBLICATIONS 2018

1)    d’Orange M, Aurégan G, Cheramy D, Gaudin-Guérif M, Lieger S, Guillermier M, Stimmer L, Joséphine C, Hérard AS, Gaillard MC, Petit F, Kiesslings MC, Schmitz C, Colin M, Buee L, Panayi F, Diguet E, Brouillet E, Hantraye P, Bemelmans AP, Cambon K (2017) Potentiating tangle formation reduces acute toxicity of soluble Tau species in the rat. Brain, in press.

2)    Laurent C, Buée L, Blum D (2018) Tau and neuroinflammation: what impact for Alzheimer’s disease and Tauopathies. Biomed J, in press.

3)    Vercruysse O, Paquet C, Gabelle A, Delbeuck X, Blanc F, Wallon D, Dumurgier J, Magnin E, Martinaud O, Jung B, Bousiges O, Lehmann S, Delaby C, Quillard-Murain M, Peoc’h K, Laplanche JL, Bouaziz-Amar E, Hannequin D, Sablonniere B, Buee L, Hugon J, Schraen S, Pasquier F, Bombois S. Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF biomarkers. Curr Alz Res, in press.

 

PUBLICATIONS 2017

4)    Dourlen P, Fernandez-Gomez F, Dupont C, Grenier-Boley B, Bellenguez C, Obriot H, Caillierez R, Sottejeau Y, Chapuis J, Bretteville A, Abdelfettah F, Delay C, Malmanche N, Soininen H, Hiltunen M, Galas MC, Amouyel P, Sergeant N, Buée L, Dermaut B, Lambert JC (2017) Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology. Mol Psychiatr, 22(6):874-883. doi: 10.1038/mp.2016.59.

5)    Goiran T, Duplan E, Chami M, Bourgeois A, El Manaa W, Rouland L, Dunys J, Lauritzen I, You H, Stambolic V, Biféri MG, Barkats M, Pimplikar SW, Sergeant N, Colin M, Morais VA, Pardossi-Piquard R, Checler F, Alves da Costa C (2017) β-Amyloid Precursor Protein Intracellular Domain Controls Mitochondrial Function by Modulating Phosphatase and Tensin Homolog-Induced Kinase 1 Transcription in Cells and in Alzheimer Mice Models. Biol Psychiatry. pii: S0006-3223(17)31515-9.

6)    Huin V, Buée L, Behal H, Labreuche J, Sablonnière B, Dhaenens CM (2017) Alternative promoter usage generates novel shorter MAPT mRNA transcripts in Alzheimer’s disease and progressive supranuclear palsy brains. Sci Rep, 7(1):12589. doi: 10.1038/s41598-017-12955-7.

7)    Jumeau F, Chalmel F, Fernandez-Gomez FJ, Carpentier C, Obriot H, Tardivel M, Caillet-Boudin ML, Rigot JM, Rives N, Buée L, Sergeant N, Mitchell V (2017) Defining the human sperm microtubulome: an integrated genomics approach. Biol Reprod, 96(1) 93-106. doi: 10.1095/biolreprod.116.143479.

8)    Laurent C, Dorothée G, Hunot S, Martin E, Monnet Y, Duchamp M, Duong Y, Légeron FP, Leboucher A, Burnouf S, Faivre E, Carvalho K, Caillierez R, Zommer N, Demeyer D, Jouy N, Sazdovitch V, Schraen-Maschke S, Delarasse C, Buée L*, Blum D* (2017) Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of Tauopathy. Brain, 140(Pt 1):184-200. doi: 10.1093/brain/aww270. Voir la vidéo sur Youtube

9)    Lebouvier T, Pasquier F, Buée L (2017) Update on Tauopathies. Curr Op Neurol, 30(6):589-598.

10) Marciniak E, Leboucher A, Caron E, Ahmed T, Tailleux A, Dumont J, Issad T, Gerhardt E, Pagesy P, Vileno M, Bournonville C, Hamdane M, Bantubungi K, Lancel S, Demeyer D, Eddarkaoui S, Vallez E, Vieau D, Humez S, Faivre E, Grenier-Boley B, Outeiro TF, Staels B, Amouyel P, Balschun D, Buee L*, Blum D* (2017) Tau deletion promotes brain insulin resistance. J Exp Med, 214(8):2257-2269. doi: 10.1084/jem.20161731.

11) Moulin S, Leys D, Schraen-Maschke S, Bombois S, Mendyk AM, Muhr-Tailleux A, Cordonnier C, Buee L, Pasquier F, Bordet R (2017) Aβ1-40 and Aβ1-42 plasmatic levels in Stroke: Influence of pre-existing cognitive status and stroke characteristics. Curr Alzheimer Res 14(6): 686-694.

12) Mudher A, Brion JP, Avila J, Medina M, Buée L (2017) EuroTau meeting: Towing scientists to Tau without tautology. Acta Neuropathol Commun, 5: 90.

13) Mudher A, Colin M, Dujardin S, Medina M, Dewachter I, Alvavi Naini SM, Mandelkow EM, Mandelkow E, Buée L, Goedert M, Brion JP (2017) What is the evidence that Tau pathology spreads through a prion-like propagation ? Acta Neuropathol Comm, 5: 99.

14) Paban V, Loriod B, Villard C, Buée L, Blum D, Pietropaolo S, Cho YH, Gory-Faure S, Mansour E, Gharbi A, Alescio-Lautier B (2017) Omics analysis of mouse brain models of human diseases. Gene, 600:90-100. doi: 10.1016/j.gene.2016.11.022.

15) Shelkovnikova TA, Dimasi P, Kukharsky M, An H, Quintiero A, Schirmer C, Buée L, Galas MC, Buchman VL (2017) Chronically stressed or stress-preconditioned neurons fail to maintain stress granule assembly. Cell Death Dis, 8(5):e2788. doi: 10.1038/cddis.2017.199.

16) Šimić G, Leko MB, Wray S, Harrington C, Delalle I, Jovanov-Milošević N, Bažadona D, Buée L, Silva R, Giovanni GD, Wischik C, Hof PR (2017) Monoaminergic Neuropathology in Alzheimer’s disease. Prog Neurobiol, 151 : 101-138. http://dx.doi.org/10.1016/j.pneurobio.2016.04.001.

17) Sotiropoulos I, Galas MC, Silva JM, Skoulakis E, Wegmann S, Maina MB, Blum D, Sayas CL, Mandelkow EM, Mandelkow E, Spillantini MG, Sousa N, Avila J, Medina M, Mudher A, Buee L (2017) Atypical, non-standard functions of the microtubule-associated Tau protein. Acta Neuropathol Comm, 5: 91.

18) Vanden Dries V, Stygelbout V, Pierrot N, Yilmaz Z, Suain V, De Decker R, Buée L, Octave JN, Brion JP, Leroy K (2017) Amyloid precursor protein reduction enhances the formation of neurofibrillary tangles in a mutant tau transgenic mouse model. Neurobiol Aging pii: S0197-4580(17)30114-8. doi: 10.1016/j.neurobiolaging.2017.03.031.

 

PUBLICATIONS 2016

19) Audouard E, Houben S, Masaracchia C, Yilmaz Z, Suain V, Authelet M, De Decker R, Buée L, Boom A, Leroy K, Ando K, Brion JP (2016) High molecular weight PHF from Alzheimer brain induce seeding of wild-type mouse tau into an argyrophilic 4R tau pathology in vivo. Am J Pathol, 186(10):2709-22. doi: 10.1016/j.ajpath.2016.06.008.

20) Barthelemy NR, Gabelle A, Hirtz C, Fenaille F, Sergeant N, Schraen-Maschke S, Vialaret J, Buée L, Junot C, Becher F, Lehmann S (2016) Differential mass spectrometry profiles of tau protein in the cerebrospinal fluid of patients with Alzheimer’s disease, progressive supranuclear palsy, and dementia with Lewy bodies. J Alz Dis, 51(4):1033-43. doi: 10.3233/JAD-150962.

21) Barthelemy NR, Fenaille F, Hirtz C, Sergeant N, Schraen-Maschke S, Vialaret J, Buée L, Gabelle A, Junot C, Lehmann S, Becher F (2016) Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity. J Proteome Res, 15(2):667-76. doi: 10.1021/acs.jproteome.5b01001.

22) Batalha VL, Ferreira D, Coelho JE, Valadas JS, Gomes R, Temido-Ferreira M, Shmidt T, Baqi Y, Buée L, Müller CE, Hamdane M, Outeiro TF, Bader M, Meijsing SH, Sadri-Vakili G, Blum D and Lopes LV (2016) The caffeine-binding adenosine A2A receptor induces age-like HPA-axis dysfunction by targeting glucocorticoid receptor function. Sci Rep, 6:31493. doi: 10.1038/srep31493.

23) Chen W, Abud EM, Yeung ST, Lakatos A, Nassi T, Wang J, Blum D, Buee L, Poon WW, Blurton-Jone M (2016) Increased Tauopathy drives microglia-mediated clearance of beta-amyloid Acta Neuropathologica Communications, 4(1):63. doi: 10.1186/s40478-016-0336-1.

24) Domise M, Didier S, Marinangeli C, Zhao H, Chandakkar P, Buee L, Viollet B, Davies P, Marambaud P, Vingtdeux V (2016) AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo. Sci Rep, 6:26758. doi: 10.1038/srep26758.

25) Garcia-Gomez BE, Fernandez-Gomez FJ, Munoz-Delgado E, Buée L, Blum D, Vidal CJ (2016) mRNA levels of Ach-related enzymes in the hippocampus of THY-Tau22 mouse: a model of human tauopathy with no signs of motor disturbance. J Mol Neurosci, 58(4):411-5. doi: 10.1007/s12031-015-0699-y.

26) Huin V. Deramecourt V, Caparros-Lefebvre D, Maurage CA, Duyckaerts C, Kovari E, Pasquier F, Buée-Scherrer V, Labreuche J, Behal H, Buée L, Dhaenens CM, Sablonnière B (2016) The MAPT gene is differentially methylated in the progressive supranuclear palsy brain. Mov Disord, 31(12):1883-1890. doi: 10.1002/mds.26820.

27) Kenisberg PA, Aquino JP, Bérard A, Gzil F, Andrieu S, Banerjee S, Brémond F, Buée L, Cohen-Mansfirld J, Mangialasche F, Platel H, Salmon E. Robert P (2016) Dementia beyond 2025: knowledge and uncertainties. Dementia (London), 15(1)6-21. doi: 10.1177/1471301215574785.

28) Laurent C, Burnouf S, Ferry B, Batalha VL, Coelho JE, Baqi Y, Mariciniak E, Parrot S, Van der Jeugd A, Faivre E, Flaten V, Ledent C, D’Hooge R, Sergeant N, Hamdane M, Humez S, Müller CE, Lopes LV, Buée L, Blum D. A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Mol Psychiatr, 2016, 21(1):97-107.

29) Magnin E, Démonet JF, Wallon D, Dumurgier J, Troussière AC, Jager A, Duron E, Gabelle A, de la Sayette V, Volpe-Gillot L, Tio G, Evain S, Boutoleau Bretonnière C, Enderle A, Mouton-Liger F, Robert P, Hannequin D, Pasquier F, Hugon J, Paquet C, on behalf of ePLM collaborators (S Lehmann, L Buée, S Schraen, F Blanc, S Bombois, O Bousiges, D Campion, B Cretin, C Delaby, B Jung, JL Laplanche, M Sauvée, C Miguet-Alfonsi, K Peoc’h, N Philippi, M Quillard-Muraine, B Sablonnière, J Touchon, O Vercruysse). Primary progressive aphasia in the network of French Alzheimer plan memory centers. J Alz Dis, 54(4):1459-1471.

30) Mansuroglu Z, Benhelli-Mokrani H, Marcato V, Sultan A, Violet M, Chauderlier A, Delattre L, Loyens A, Talahari S, Begard S, Nesslany F, Colin M Souès S, Lefebvre B, Buee L, Galas MC, Bonnefoy E. Loss of Tau protein affects the structure, transcription and repair of neuronal pericentromeric heterochromatin. Sci Rep, 6:33047. doi: 10.1038/srep33047.

31) Papegaey A, Eddarkaoui S, Deramecourt V, Fernandez-Gomez FJ, Pantano P, Obriot H, Machala C, Anquetil V, Camuzat A, Brice A, Maurage CA, Le Ber I, Duyckaerts C, Buée L, Sergeant N, Buée-Scherrer V (2016) Reduced Tau protein expression is associated with frontotemporal dementia with progranulin mutation. Acta Neuropathol Comm, 4(1):74. doi: 10.1186/s40478-016-0345-0.

32) Šimić G, Leko MB, Wray S, Harrington C, Delalle I, Jovanov-Milošević N, Danira Bažadona D, Buée L, De Silva R, Di Giovanni G, Wischik C, Hof PR (2016) Tau protein hyperphosphorylation and aggregation in Alzheimer’s disease and other tauopathies, and possible neuroprotective strategies. Biomolecules 6(1):6. doi: 10.3390/biom6010006.

33) Tardivel M, Begard S, Bousset L, Dujardin S, Coens A, Melki R, Buée L*, Colin M* (2016) Tunneling nanotube-mediated neuron to neuron transfer of pathological Tau protein assemblies. Acta Neuropathol Comm, 4:117 doi: 10.1186/s40478-016-0386-4.

 

PUBLICATIONS 2015

34) Ahmed T, Blum D, Burnouf S, Demeyer D, Buée-Scherrer V, D’Hooge R, Buée L, Balschun D (2015) Rescue of impaired late-phase LTD in a tau transgenic mouse model. Neurobiol Aging, 36(2) 730-39.

35) Blum D, Herrera F, Gerhardt E, Francelle L, Basquin M, Obriot H, Sergeant N, Brouillet E, Buée L, Outeiro TF (2015) The impact of Huntingtin mutation on Tau phosphorylation and subcellular distribution. Hum Mol Genet, 24(1):76-85.

36) Burlot MA, Braudeau J, Michaelsen-Preusse K, Potier B, Ayciriex S, Varin J, Gautier B, Djelti F, Audrain M, Dauphinot L, Fernandez-Gomez FJ, Caillierez R, Laprevote O, Bieche I, Auzeil N, Potier MC, Dutar P, Korte M, Buee L, Blum D, Cartier N (2015) Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology. Hum Mol Genet, 24(21) 5965-76.

37) Caillet-Boudin ML, Buée L, Sergeant N, Lefebvre B (2015) Regulation of human MAPT gene expression. Mol Neurodegener, 10:28.

38) Caparros-Lefebvre D, Golbe LI, Deramecourt V, Maurage CA, Huin V, Buée-Scherrer V, Obriot H, Sablonnière B, Caparros F, Buée L, Lees AJ (2015) A geographical cluster of progressive supranuclear palsy in Northern France. Neurology, 85(15) 1293-300.

39) Delaby C, Gabelle A, Blum D, Schraen-Maschke S, Moulinier A, Boulangien J, Severac D, Buee L, Reme T, Lehmann S (2015) Central nervous system and peripheral inflammatory processes in Alzheimer’s disease: biomarker profiling approach. Frontiers in Neurology, 6:181.

40) Derisbourg M, Leghay C, Chiappetta G, Fernandez-Gomez FJ, Laurent C, Demeyer D, Carrier S, Buée-Scherrer V, Blum D, Vinh J, Sergeant N, Verdier Y, Buée L, Hamdane M (2015) Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Sci Rep, 5:9659.

41) Dujardin S, Colin M, Buée L (2015) Animal models of tauopathies and their implications for research/translation into the clinic. Neuropathol Appl Neurobiol, 41, 59–80.

42) Duyckaerts C, Braak H, Brion JP, Buée L, Del Tredici K, Goedert M, Halliday G, Neumann M, Spillantini MG, Tolnay M, Uchihara T (2015) PART is part of Alzheimer disease. Acta Neuropathol, 129(5):749-56.

43) Frederick C, Ando K, Leroy K, Heraud C, Buée L, Brion JP (2015) Rapamycin ester analog CCI-779/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice. J Alzheimers Dis, 44(4):1145-56.

44) Gabelle A, Schraen S, Gutierrez LA, Pays C, Rouaud O, Buée L, Touchon J, Helmer C, Lambert JC, Berr C (2015) Plasma β-amyloid 40 levels are positively associated with mortality risks in the elderly. Alzheimers & Dementia, 11(6) 672-80.

45) Giustiniani J, Guillemeau K, Dounane O, Sardin E, Huvent I, Schmitt A, Hamdane M, Buée L, Landrieu I, Lippens G, Baulieu EE, Chambraud B (2015) The FK506-Binding Protein FKBP52 in vitro induces the aggregation of different truncated Tau forms that show prion-like behavior. FASEB J, 29(8)3171-81.

46) Goodwin M, Mohan A, Batra R, Lee KY, Charizanis K, Fernández Gómez FJ, Eddarkaoui S, Sergeant N, Buée L, Kimura T, Dalton J, Takamura K, Day JW, Swanson MS (2015) MBNL sequestration by toxic RNAs and RNA mis-Processing in the Myotonic Dystrophy brain. Cell Reports, 12(7)1159-68.

47) Kaffashian S, Tzourio C, Soumaré A, Dufouil C, Mazoyer B, Schraen Maschke S, Buee L, Debette S (2015) Association of plasma amyloid-ß with MRI markers of structural brain aging. Neurobiol Aging, 36(10)2663-70.

48) Kim DK, Lee J, Kim SR, Choi DS, Yoon YJ, Kim JH, Go G, Nhung D, Hong K, Jang SC, Kim SH, Park KS, Kim OY, Park HT, Seo JH, Aikawa E, Baj-Krzyworzeka M, WM Bas van Balkom, Belting M, Blanc L, Bond V, Bongiovanni A, Borràs FE, Buée L, Buzás EI, Cheng L, Clayton A, Cocucci E, Dela Cruz C, Desiderio DM, Karin Ekström K, Juan M. Falcon-Perez JM, Gardiner C, Giebel B, Greening D, Gross JC, Gupta D, Hendrix A, Hill AF, Hill MM, Hoen EN, Hwang DW, Inal J, Jagannadham MV, Jayachandran M, Jee YK, Jørgensen M, Kim KP, Kim YK, Kislinger T, Lässer C, Lee DS, Lee H, van Leeuwen J, Lener T, Liu ML, Lötvall J, Marcilla A, Mathivanan S, Möller A, Morhayim J, Mullier F, Nieuwland R, Nunes DN, Pang K, Park J, Patel T, Pocsfalvi G, del Portillo H, Putz U, Ramirez MI, Rodrigues ML, Roh TY, Royo F, Sahoo S, Schiffelers R, Sharma S, Siljander P, Simpson R, Soekmadji C, Stahl P, Stensballe A, Stępień E, Tahara H, Trummer A, Valadi H, Vella LJ, Vizio DD, Wai SN, Witwer K, Yáñez-Mó M, Youn H, Zeidler R, Gho YS (2015) EVpedia: A Community Web Portal for Extracellular Vesicles Research. Bioinformatics, 31(6):933-9.

49) Marciniak E, Faivre E, Dutar P, Alves Pires C, Demeyer D, Caillierez R, Laloux C, Buée L, Blum D, Humez S (2015) The Chemokine MIP-1alpha/CCL3 impairs mouse hippocampal synaptic transmission, plasticity and memory. Sci Rep, 5 :15862.

50) Martel G, Simon A, Nocera S, Kalainathan S, Pidoux L, Blum D, Leclère-Thurbant S, Diaz J, Geny D, Moyse E, Videau C, Buée L, Epelbaum J, Viollet C (2015) Aging, but not Tau pathology, impacts olfactory performances and somatostatin systems in THY-Tau22 mice. Neurobiol Aging, 36(2):1013-28.

51) Melnyk P, Vingtdeux V, Burlet S, Eddarkaoui S, Grosjean ME, Larchanche PE, Hochart G, Sergheraert C, Estrella C, Barrier M, Poix V, Plancq P, Lannoo C, Hamdane M, Delacourte A, Verwaerde P, Buee L, Sergeant N (2015) Chloroquine- and chloroquinoline-derivatives as models for the design of modulators of Amyloid Peptide Precursor metabolism. ACS Chem Neurosci, 6(4):559-69.

52) Moas-Heloire V, Renault N, Batalha V, Arias AR, Marchivie M, Yous S, Deguine N, Buee L, Chavatte P, Blum D, Lopes L, Melnyk P, Agouridas L (2015) Design and synthesis of fused tetrahydroisoquinoline-iminoimidazolines. Eur J Med Chem 106 :15-25. doi: 10.1016/j.ejmech.2015.10.030.

53) Multhaup G, Huber O, Buee L, Galas MC (2015) APP metabolites AICD, Aβ42 and Tau in nuclear roles. J Biol Chem, 290(39)23515-22.

54) Qi H, Cantrelle FX, Benhelli-Mokrani H, Smet-Nocca C, Buée L, Lippens G, Bonnefoy E, Galas MC, Landrieu I (2015) Nuclear Magnetic Resonance Spectroscopy characterization of Tau interaction with DNA and its regulation by phosphorylation. Biochemistry, 54(7):1525-33.

55) Rosseels J, Van den Brande J, Violet M, Jacobs D, Grognet P, Lopez J, Huvent I, Caldara M, Swinnen E, Papegaey A, Caillierez R, Buée-Scherrer V, Engelborghs S, Lippens G, Colin M, Buée L, Galas M, Vanmechelen E, Winderickx J (2015) Tau Monoclonal Antibody Generation based on Humanized Yeast Models: Impact on Tau Oligomerization and Diagnostics. J Biol Chem 290(7):4059-74.

56) Smith PY, Hernandez-Rapp J, Jolivette F, Lecours C, Bisht K, Goupil C, Parsi S, Morin F, Planel E, Bennett DA, Fernandez-Gomez FJ, Sergeant N, Buee L, Tremblay ME, Calon F, Hebert SS (2015) miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo. Hum Mol Genet 24(23)6721-35. doi: 10.1093/hmg/ddv377.

57) Violet M, Chauderlier A, Delattre L, Tardivel M, Sendid Chouala M, Marciniak E, Humez S, Binder L, Kayed R, Lefebvre B, Bonnefoy E, Buée L, Galas MC (2015) Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo. Neurobiol Dis 82:540-51.

 

PUBLICATIONS 2014

58) Ahmed T, Van der Jeugd A, Blum D, Galas MC, Balschun D, Buée L, d’Hooge R (2014)  Behavioural and hippocampal synaptic plasticity in an homozygous tau deletion. Neurobiol Aging, 35(11):2474-8.

59) Caillet-Boudin ML, Fernandez-Gomez FJ, Tran H, Dhaenens CM, Buee L, Sergeant N (2014) Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy. Front Mol Neurosci 6:57.

60) Carpentier C, Ghanem D, Fernandez-Gomez FJ, Jumeau F, Philippe JV, Freyermuth  F, Labudeck A, Eddarkaoui S, Dhaenens CM, Holt I, Behm-Ansmant I, Marmier-Gourrier N, Branlant C, Charlet-Berguerand N, Marie J, Schraen-Maschke S, Buée L, Sergeant N, Caillet-Boudin ML (2014) Tau exon 2 responsive elements deregulated in myotonic dystrophy type I are proximal to exon 2 and synergistically regulated by MBNL1 and MBNL2. Biochim Biophys Acta – Molecular Basis of Disease 1842(4): 654-64.

61) Chaala A, Poirier R, Blum D, Gillet B, Le Blanc P, Basquin M, Buée L, Laroche S & Enderlin V (2014) Hypothyroidism induces Alzheimer’s disease-related pathological hallmarks and associated memory impairments. Hippocampus 24(11):1381-93.

62) Charton J, Gauriot M, Guo Q, Hennuyer N, Marechal X, Dumont J, Hamdane M, Pottiez V, Landry V, Sperandio O, Flipo M, Buee L, Staels B, Leroux F, Tang WJ, Deprez B, Deprez-Poulain R (2014) Imidazole-derived 2 – [N-carbamoylmethyl – alkylamino] acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-β hydrolysis. Eur J Med Chem 79:184-93.

63) Chouraki V, De Bruijn RF, Chapuis J, Bis JC, Reitz C, Schraen S, Ibrahim-Verbaas CA, Grenier-Boley B, Delay C, Rogers R, Demiautte F, Mounier A, Fitzpatrick AL; The Alzheimer’s Disease Neuroimaging Initiative, Berr C, Dartigues JF, Uitterlinden AG, Hofman A, Breteler M, Becker JT, Lathrop M, Schupf N, Alpérovitch A, Mayeux R, van Duijn CM, Buée L, Amouyel P, Lopez OL, Ikram MA,  Tzourio C, Lambert JC (2014) A genome-wide association meta-analysis of plasma Aβ peptides concentrations in the elderly. Mol Psychiatry, 19(12):1326-35.

64) Delplanque J, Devos D, Huin V, Genet A, Sand O, Moreau C, Goizet C, Charles P, Anheim M, Monin ML, Buée L, Destée A, Grolez G, Delmaire C, Dujardin K, Dellacherie D, Brice A, Stevanin G, Strubi-Vuillaume I, Dürr A, Sablonnière B (2014) TMEM240 mutations cause spinocerebellar ataxia 21 with mental retardation and severe cognitive impairment. Brain 137(Pt 10):2657-63.

65) Dujardin S, Bégard S, Caillierez R, Lachaud C, Delattre L, Carrier S, Loyens A, Galas MC, Bousset L, Melki R, Auregan G, Hantraye P, Brouillet E, Buée L*, Colin M* (2014) Ectosomes: A new mechanism for non-exosomal secretion of Tau protein. PLoS One, 9(6):e100760.

66) Dujardin S, Lécolle K, Caillierez R, Bégard S, Zommer N, Lachaud C, Carrier S, Dufour N, Aurégan G, Winderickx J, Hantraye P, Déglon N, Colin M*, Buée L* (2014) Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol Commun 2(1):14.

67) Fernandez-Gomez FJ, Jumeau F, Derisbourg M, Burnouf S, Tran H, Eddarkaoui S, Obriot H, Dutoit-Lefevre V, Deramecourt V, Mitchell V, Lefranc D, Hamdane M, Blum D, Buee L, Buée-Scherrer V & Sergeant N (2014) Consensus brain-derived protein, extraction protocol for the study of human and murine brain proteome using both 2D-DIGE and mini 2DE immunoblotting. J Vis Exp 10 ;(86).

68) Flaten V, Laurent C, Coelho JE, Sandau U, Batalha VL, Burnouf S, Hamdane M, Humez S, Boison D, Lopes LV, Buée L, Blum D (2014) From epidemiology to pathophysiology: what about caffeine in Alzheimer’s disease? Biochem Soc Trans 42(2):587-92.

69) Gelé P, Vingtdeux V, Potey C, Drobecq H, Ghestem A, Melnyk P, Buée L, Sergeant N, Bordet R (2014) Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke. Proteome Sci 12:24.

70) Kaffashian S, Tzourio C, Soumaré A, Dufouil C, Zhu Y, Crivello F, Maillard P, Schraen Maschke S, Mazoyer B, Buee L, and Debette S (2014) Plasma amyloid-ß and MRI markers of cerebral small vessel disease. Neurology, 83(22):2038-45.

71) Laurent C, Eddarkaoui S, Derisbourg M, Leboucher A, Demeyer D, Carrier S, Schneider M, Hamdane M, Müller CE, Buée L, Blum D (2014) Beneficial effects of caffeine in a transgenic model of Alzheimer’s Disease-like Tau pathology. Neurobiol Aging, 35(9):2079-90.

72) Sigala J, Jumeau F, Caillet-Boudin ML, Sergeant N, Ballot C, Rigot JM, Marcelli F, Tardivel M, Buée L, Mitchell V (2014) Immunodetection of Tau microtubule-associated protein in human sperm and testis. Asian J Androl 16(6):927-8.

73) Violet M, Delattre L, Tardivel M, Sultan A, Chauderlier A, Caillierez R, Talahari S, Nesslany F, Lefebvre B, Bonnefoy E, Buée L, Galas MC (2014) A major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditions. Front Cell Neurosci. 2014 Mar 18;8:84.

 

PUBLICATIONS 2013

74) Ando K, Sambo AV, Dourlen P, Bretteville A, Belarbi K, Vingtdeux V, Eddarkoui S, Drobecq H, Ghestem A, Bégard S, Demey-Thomas E, Melnyk P, Smet C, Lippens G, Maurage CA, Caillet-Boudin ML, Verdier Y, Vinh J, Landrieu I, Galas MC, Blum D, Hamdane M, Sergeant N, Buee L (2013) Pin1 post-translational modifications are modulated by Tau pathology and may be relevant as biomarker. Neurobiol Aging 34(3):757-69.

75) Bombois S, Duhamel A, Salleron J, Deramecourt V, Mackowiak MA, Deken V, Sergeant N, Pasquier F, Buée L, Sablonnière B, Schraen-Maschke S (2013) A new decision tree combining Aß1-42 and pTau levels in Alzheimer’s diagnosis. Curr Alzheimer Res, 10(4):357-64.

76) Burnouf S, Martire A, Derisbourg M, Laurent C, Belarbi K, Leboucher A, Fernandez-Gomez FJ, Troquier L, Eddarkaoui S, Grosjean ME, Demeyer D, Muhr-Tailleux A, Buisson A, Sergeant N, Hamdane M, Humez S, Popoli P, Buée L, Blum D (2013) NMDA receptor dysfunction contributes to impaired BDNF-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model. Aging Cell, 12(1): 11-23.

77) Caillierez R, Bégard S, Lécolle K, Deramecourt V, Zommer N, Dujardin S, Loyens A, Dufour N, Aurégan G, Winderickx J, Hantraye P, Déglon N, Buée L* and Colin M* (2013) Lentiviral delivery of the human wild-type Tau protein mediates a slow and progressive neurodegenerative Tau pathology in the rat brain. Mol Ther 21(7):1358-68.

78) Chapuis J, Hansmannel F, Gistelinck M, Mounier A, Van Cauwenberghe C, Van Kolen K, Geller F, Sottejeau Y, Harold D, Dourlen P, Grenier-Boley B, Kamatani Y, Delepine B, Demiautte F, Zelenika D, Zommer N, Hamdane M, Bellenguez C, Dartigues JF, Hauw JJ, Letronne F, Ayral AM, Sleegers K, Schellens A, Vanden Broeck L, Engelborghs S, Paul De Deyn P, Vandenberghe R, O’Donovan M, GERAD consortium, Owen M, Epelbaum J, Mercken M, Karran E, Bantscheff M, Drewes G, Joberty G, Campion D, Octave JN, Berr C, Lathrop M, Callaerts P, Mann D, Williams J, Buée L, Dewachter I, Van Broeckhoven C, Amouyel P, Moechars D, Dermaut B, Lambert JC (2013) Increased Expression of BIN1 Mediates Alzheimer Genetic risk by Modulating Tau Pathology. Mol Psychiatr 18(11):1225-34.

79) Chaunu MP, Deramecourt V, Buée-Scherrer V, Le Ber I, Brice A, Ehrle N, El Hachimi K, Pluot M, Maurage CA, Bachkine S, Buée L (2013) Juvenile frontotemporal dementia with parkinsonism associated with Tau mutation G389R. J Alzheimers Dis. 37(4):769-76.

80) Gabelle A, Dumurgier J, Vercruysse O, Paquet C, Bombois S, Laplanche JL, Peoc’h K, Schraen S, Buée L, Pasquier F, Hugon J, Touchon J, Lehmann S (2013) Impact of the 2008-2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study. J Alzheimers Dis. 34(1):297-305.

81) Gabelle A, Richard F, Gutierrez LA, Schraen S, Delva F, Rouaud O, Buée L, Dartigues JF, Touchon J, Lambert JC, Berr C (2013) Plasma Amyloid-β Levels and Prognosis in Incident Dementia Cases of the 3-City Study. J Alzheimers Dis 33(2):381-91.

82) Hernández-Hernández O, Guiraud-Dogan C, Sicot G, Huguet A, Luilier S, Steidl E, Saenger S, Marciniak E, Obriot H, Chevarin C, Nicole A, Revillod L, Charizanis K, Lee KY, Suzuki Y, Kimura T, Matsuura T, Cisneros B, Swanson MS, Troveo F, Buisson B, Bizot JC, Hamon M, Humez S, Bassez G, Metzger F, Buée L, Munnich A, Sergeant N, Gourdon G, Gomes-Pereira M (2013) Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behavior. Brain, 136: 957-970.

83) Hernández-Hernández O, Sicot G, Dinca DM, Huguet A, Nicole A, Buée L, Munnich A, Sergeant N, Gourdon G, Gomes-Pereira M (2013) Synaptic protein dysregulation in myotonic dystrophy type 1: Disease neuropathogenesis beyond missplicing. Rare Dis. 2013 Jun 26;1:e25553.

84) Huin V, Vasseur F, Schraen-Maschke S, Dhaenens CM, Devos P, Dupont K, Sergeant N, Buée L, Lacour A, Hofmann-Radvanyi H, Sablonnière B (2013) MBNL1 gene variants as modifiers of disease severity in myotonic dystrophy type 1. J Neurol 260(4): 998-1003.

85) Lambert JC, Grenier-Boley B, Harold D, Zelenika D, Chouraki V, Kamatani Y, Sleegers K, Ikram A, Hiltunen M, Reitz C, Mateo I, Feulner T, Bullido M, Galimberti D, Concari L, Alvarez V, Sims R, Gerrish A, Chapman J, Deniz-Naranjo C, Solfrizzi V, Sorbi S, Arosio B, Spalletta G, Siciliano G, Epelbaum J, Hannequin D, Dartigues JF, Tzourio C, Berr C, Schrijvers EMC, Rogers R, Tosto G, Pasquier F, Bettens K, Van Cauwenberghe C, Fratiglioni L, Graff C, Delepine M, EADI consortium, GERAD consortium, Ferri R, Reynolds CA, Lannfelt L, Ingelsson M, Prince JA, Chillotti C, Greco A, Seripa D, Boland A, Mancuso M, Bossù P, Annoni G, Nacmias B, Bosco P, Panza F, Sanchez-Garcia F, Del Zompo M, Coto E, Owen M, O’Donovan M, Valdivieso F, Caffara P, Scarpini E, Combarros O, Buée L, Campion D, Soininen H, Breteler M, Riemenschneider M, Van Broeckhoven C, Alpérovitch A, Lathrop M, Trégouët DA, Williams J, Amouyel P (2013) Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer’s disease. Mol Psychiatr 18(4): 461-470.

86) Leboucher A, Laurent C, Fernandez-Gomez FJ, Burnouf S, Troquier L, Eddarkaoui S, Demeyer D, Caillierez R, Zommer N, Vallez E, Bantubungi K, Breton C, Pigny P, Buée-Scherrer V, Staels B, Hamdane M, Tailleux A, Buée L, Blum D (2013) Detrimental Effects of Diet-Induced Obesity on τ Pathology Is Independent of Insulin Resistance in τ Transgenic Mice. Diabetes, 62(5):1681-8.

87) Lécolle K, Bégard S, Caillierez R, Grellier E, Loyens A, Beauvillain JC, D’Halluin JC, Baroncini M, Lejeune JP, Sharif A, Prévot V, Dournaud P, Buée L, Colin M (2013) Somatostatin receptor type 2: a relevant target for the selective delivery of genes into human glioblastoma cells using fiber-modified adenoviral vectors. Gene Therapy 20(3): 283-297.

88) Lo A, Iscru E, Blum D, Tesseur I, Callaerts-Vegh Z, Buee L, De Strooper B, Balschun D & D’Hooge R (2013) Amyloid and tau neuropathology differentially affect prefrontal synaptic plasticity and cognitive performance in mouse models of Alzheimer’s disease. J Alzheimers Dis 37:109-25.

89) Moreau C, Delval A, Tiffreau V, Defevbre L, Dujardin K, Duhamel A, Petyt G, Hosseil-Foucher C, Blum D, Sablonniere B, Schaen-Maschke S, Allorge D, Destee A, Bordet R & Devos D (2013) Memantine for axial signs in Parkinson’s disease: a randomized, double-blind, placebo-controlled pilot study. Journal of Neurology, Neurosurgery & Psychiatry 84(5):552-5.

90) Simonin C, Duru C, Salleron J, Hincker P, Charles P, Delval A, Youssov K, Burnouf S, Azulay JP, Verny C, Tranchant C, Goizet C, Defebvre L, Sablonnière B, Rousseau M, Buée L, Destée A, Godefroy O, Dürr A, Landwehrmeyer B, Bachoud-Levi AC, Richard F, Blum D, Krystkowiak P (2013) Association between caffeine intake and age at onset in Huntington’s disease. Neurobiol Dis 58:179-182.

91) Van der Jeugd A, Blum D, Raison S, Buée L, D’Hooge R (2013) Observations in THY-Tau22 mice that resemble behavioural and psychological signs and symptoms of dementia. Behav Brain Res 242:34-9.

92) Van der Jeugd A, Vermarcke B, Blum D, Derisbourg M, Hamdane M, Buee L, Op de Beeck H & D’Hooge R (2013) Progressive age-related cognitive decline in Tau mice. J Alzheimers Dis 37(4):777-88.